We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
-12.11%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$454M
AUM Growth
-$60.5M
Cap. Flow
+$18.4M
Cap. Flow %
4.05%
Top 10 Hldgs %
94.65%
Holding
18
New
1
Increased
4
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
RPTP
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
+$11M
2
SEEL
Seelos Therapeutics, Inc. Common Stock
SEEL
+$8.6M
3
ARRY
Array Biopharma Inc
ARRY
+$6.52M
4
MDCO
Medicines Co
MDCO
+$6.04M
5
ESPR
Esperion Therapeutics
ESPR
+$2.98M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$14.6M
2
ANIP icon
ANI Pharmaceuticals
ANIP
+$1.4M

Sector Composition

Rank Sector Weight
1 Healthcare 84.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABBV icon
1
AbbVie
ABBV
$443B
$90.2M 19.89%
1,580,000
– –
ARIA
2
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$82.1M 18.09%
12,850,000
– –
BIIB icon
3
Biogen
BIIB
$30B
$80.7M 17.78%
310,000
– –
MDCO
4
DELISTED
Medicines Co
MDCO
$55.7M 12.27%
1,752,000
+185,000
+12% +$6.04M
DGX icon
5
Quest Diagnostics
DGX
$25.7B
$41.1M 9.05%
575,000
– –
PCRX icon
6
Pacira BioSciences
PCRX
$1.04B
$28.2M 6.21%
532,200
– –
ITCI
7
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$18.8M 4.13%
675,000
– –
RPTP
8
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$12.5M 2.76%
+2,725,000
New +$11M
ESPR
9
DELISTED
Esperion Therapeutics
ESPR
$10.7M 2.36%
633,000
+185,000
+41% +$2.98M
AEGR
10
DELISTED
Aegerion Pharmaceuticals
AEGR
$9.55M 2.1%
2,580,000
– –
ARRY
11
DELISTED
Array Biopharma Inc
ARRY
$8.48M 1.87%
2,875,000
+2,175,000
+311% +$6.52M
SEEL
12
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$8.41M 1.85%
13
+7
+117% +$8.6M
VVUS
13
DELISTED
Vivus Inc
VVUS
$3.6M 0.79%
257,394
– –
AVEO
14
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$2.13M 0.47%
231,376
– –
RPRX
15
DELISTED
Repros Therapeutics Inc.
RPRX
$970K 0.21%
1,001,000
– –
AMGN icon
16
Amgen
AMGN
$208B
– –
-90,000
Closed -$14.6M
ANIP icon
17
ANI Pharmaceuticals
ANIP
$1.8B
– –
-31,000
Closed -$1.4M

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q1 2016 Portfolio in Review

As of Q1 2016, Sarissa Capital Management held 18 positions worth $454M, down 12% from $514M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Sarissa Capital Management deployed $18.4M of net new capital in Q1 2016, opening 1 new position and adding to 4 existing holdings. Its largest new stake was RAPTOR PHARMACEUTICAL CORP COM STK (DE): 2,725,000 shares worth $12.5M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 88% a quarter earlier.

On the sell side, the most notable exit was Amgen, an estimated $14.6M sold.

  • Sarissa Capital Management's largest Q1 2016 buy was RAPTOR PHARMACEUTICAL CORP COM STK (DE): 2,725,000 shares worth $12.5M.
  • Sarissa Capital Management added most to Seelos Therapeutics, Inc. Common Stock in Q1 2016, an estimated $8.6M increase.
  • Sarissa Capital Management fully exited Amgen in Q1 2016, selling an estimated $14.6M.
  • Sarissa Capital Management's ten largest holdings make up 95% of its $454M portfolio in Q1 2016.
  • Sarissa Capital Management opened 1 new position and closed 2 in Q1 2016.
  • Sarissa Capital Management's portfolio value fell 12% quarter-over-quarter to $454M.

Based on Sarissa Capital Management's 13F filing for Q1 2016, filed 16 May 2016.